Trial site
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York 10065-6800, United StatesNot linked to an institution yet
- 13running trials
- 4closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 1/28 trials
- Phase 24 trials
- Phase 34 trials
- Phase 11 trial
- Status
- Recruiting11 trials
- Completed3 trials
- Active, not recruiting2 trials
- Terminated1 trial
- Lead sponsor
- BeOne Medicines8 trials
- BeiGene1 trial
- BioNTech SE1 trial
- Caribou Biosciences, Inc.1 trial
- Daiichi Sankyo1 trial
- and 5 more
Running trials
Recruiting
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619· Phase 1/2· Eikon Therapeutics· Source
Contact: Ana C Mamede, PharmD
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548· Phase 1/2· BioNTech SE· Source
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636· Phase 1/2· Pathos AI, Inc.· Source
Contact: Nicholas Mai
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941· Phase 1/2· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037· Phase 2· BeOne Medicines· Source
Active, not recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
NCT05544552· Phase 1/2· Tyra Biosciences, Inc· Source
Recruiting
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
NCT04959903· Phase 1/2· Smart Immune SAS· Source
Contact: Jaap-Jan BOELENS, MD, PhD (principal investigator)
Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605· Phase 1/2· BeOne Medicines· Source
Contact: BeOne Medicines
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716· Phase 1/2· BeOne Medicines· Source
Contact: BeOne Medicines
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error